- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02737540
Neuropsychological Factors Associated With Vulnerability to Suicidal Behavior in Depressed Elderly Patients (SPAD)
Study Overview
Status
Conditions
Detailed Description
The secondary objectives are to confirm or explore the deficits of certain cognitive processes involved in potentially suicidal behavior in depressed elderly persons but that have been little or not studied to date. These include:
A. cognitive control and sensitivity to interference (Victoria Stroop test, incompatibility test, flexibility test, Go / No-Go);
B. Strategic recovery of semantic memory (verbal fluency test);
C. Working memory (TEA);
D. Insight related to depression (Mood Disorders Insight Scale);
E. Recognition of facial emotions;
F. Emotional regulation;
G. Negative attitudes;
H. Self-perception and;
I. Time perspectives.
Finally, patients will be contacted by telephone at month 6 to assess the occurrence of a suicidal act during this period and thus calculate the predictive ability of cognitive and psychological factors.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Nîmes, France, 30000
- Clinique Les Sophoras
-
Nîmes Cedex 09, France, 30029
- CHRU de Nîmes - Hôpital Universitaire Carémeau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria for patients:
- The patient or his/her representative must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- Patients with a diagnosis of current, moderate to severe, major depressive episode according to the DSM diagnostic criteria 5. This episode can be considered as part of a major depressive disorder or bipolar disorder.
- Patients with or without a personal history of suicide attempts. A suicide attempt is defined as any act performed with some intent to die (Mann 1998). Suicidal threats, aborted or interrupted gestures as well as self-mutilating acts without suicidal intent will not be considered as suicidal acts.
- Patients hospitalized (or followed as outpatients) in the Nîmes University Hospital psychiatry department or the Sophoras clinic in Nimes
Inclusion criteria for healthy subjects:
- The subject or his/her representative must have given his/her informed and signed consent
- The subject must be insured or beneficiary of a health insurance plan
- Non-depressed subject without personal history of lifetime mood disorder or severe mental illness, or substance or alcohol abuse during the past 12 months
Exclusion criteria for patients:
- The patient is participating in another study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection
- The patient (or his/her legal representative) refuses to sign the consent
- It is impossible to correctly inform the patient or his/her legal representative
- The patient has a known MMSE score <24 (elimination of probable dementia pathology)
- Known central neurological disease including degenerative disease, severe head trauma and severe cerebral vascular disease
- Known schizophrenia and other psychotic disorders
- Alcohol or substance abuse in the last 12 months
- Electroconvulsive therapy in the 12 months preceding the study because of the risk of mnesic side effects
- Inability to perform neuropsychological tests because of a language problem, poor understanding, a major tremor, inability to sit still, a major sight problem that can not be corrected, or other severe cognitive impairment
- The subject presents an acute somatic decompensation incompatible with the completion of this study
- The patient has current confusion
Exclusion criteria for healthy subjects:
- The subject is participating in another study
- The subject is in an exclusion period determined by a previous study
- The subject is under judicial protection
- The subject (or his/her legal representative) refuses to sign the consent
- It is impossible to correctly inform the subject or his/her legal representative
- The subject has a known MMSE score <24 (elimination of probable dementia pathology)
- Known central neurological disease including degenerative disease, severe head trauma and severe cerebral vascular disease
- Known schizophrenia and other psychotic disorders
- Alcohol or substance abuse in the last 12 months
- Electroconvulsive therapy in the 12 months preceding the study because of the risk of mnesic side effects
- Inability to perform neuropsychological tests because of a language problem, poor understanding, a major tremor, inability to sit still, a major sight problem that can not be corrected, or other severe cognitive impairment
- The subject has a mood disorder
- The subject presents an acute somatic decompensation incompatible with the completion of this study
- Thesubject has current confusion
Pharmacological treatment is not a criterion for exclusion in itself but it will be left to the judgment of the evaluator to choose to include a subject or not (or to postpone inclusion) depending on the drug (eg. after weaning daytime sedative treatment and benzodiazepines).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Major depressive episode
This study population consists of patients over 60 years of age with or without a personal history of suicide attempts, hospitalized in the Nîmes University Hospital psychiatry department or the Sophoras clinic for a major depressive episode.
|
|
Healthy subjects
Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts will be recruited.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Trust Game
Time Frame: Days 1-7
|
Days 1-7
|
|
Ultimatum Game
Time Frame: Days 1-7
|
Days 1-7
|
|
Iowa Gambling Task
Time Frame: Days 1-7
|
Days 1-7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Stroop Victoria Test
Time Frame: Days 1-7
|
Days 1-7
|
|
Incompatibility Test
Time Frame: Days 1-7
|
Days 1-7
|
|
Flexibility test
Time Frame: Days 1-7
|
Days 1-7
|
|
Go-NoGo
Time Frame: Days 1-7
|
Days 1-7
|
|
Working memory - TEA
Time Frame: Days 1-7
|
Days 1-7
|
|
Mood Disorders Insight Scale
Time Frame: Days 1-7
|
Days 1-7
|
|
Verbal fluency test
Time Frame: Days 1-7
|
Days 1-7
|
|
Future autobiographical fluency task
Time Frame: Days 1-7
|
Days 1-7
|
|
Bristol Emotion Recognition Test
Time Frame: Days 1-7
|
Days 1-7
|
|
Cognitive Emotion Regulation Questionnaire
Time Frame: Days 1-7
|
Days 1-7
|
|
Questionnaire on negative attitudes towards problems
Time Frame: Days 1-7
|
Days 1-7
|
|
Revised self-awareness scale, Self-reference task
Time Frame: Days 1-7
|
Days 1-7
|
|
Balanced Temporal Perspective Scale
Time Frame: Days 1-7
|
Days 1-7
|
|
Suicide attempt within 6 months of follow-up
Time Frame: Month 6
|
Month 6
|
Collaborators and Investigators
Investigators
- Study Director: Fabrice JOLLANT, MD, Centre Hospitalier Universitaire de Nîmes
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOCAL/2016/MW-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Gang WangWest China Hospital; The First Hospital of Hebei Medical University; Tianjin... and other collaboratorsRecruitingMajor Depressive Disorder (MDD) | Depression - Major Depressive DisorderChina
-
Brian MickeyNational Institute of Mental Health (NIMH)RecruitingMajor Depressive Episode | Depression - Major Depressive Disorder | Treatment-Resistant Major Depressive DisorderUnited States
-
Unity Health TorontoUniversity of Toronto; Toronto Metropolitan UniversityRecruitingMajor Depressive Disorder (MDD) | Major Depressive Episode | Treatment-Resistant Major Depressive DisorderCanada
-
Stanford UniversityNational Institute of Mental Health (NIMH)Recruiting
-
TakedaRecruitingMajor Depressive DisorderJapan
-
Neurocrine BiosciencesRecruitingMajor Depressive DisorderSpain, Serbia, United States, Bulgaria, Canada, Estonia, Italy, Poland, Taiwan, Australia, South Korea
-
Luye Pharma Group Ltd.Enrolling by invitationMajor Depressive DisorderChina
-
NeuroQore Inc.Makromed Inc.Enrolling by invitationMajor Depressive DisorderUnited States
-
The Royal Ottawa Mental Health CentreNot yet recruitingDepression | Major Depressive Disorder (MDD) | Depressive Episode | Depression - Major Depressive DisorderCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael